Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Clinical trial NCT04858516 · UNKNOWN
Trial details
- NCT number
- NCT04858516
- Sponsor
- Guangdong Provincial People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-30
- Primary completion
- 2024-04-30
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.